IFN-γ in Combination with IL-3 Accelerates Platelet Recovery in Mice with 5-Fluorouracil-Induced Marrow Aplasia

K TSUJI-TAKAYAMA, A HARASHIMA… - Journal of interferon & …, 1996 - liebertpub.com
K TSUJI-TAKAYAMA, A HARASHIMA, H TAHATA, N IZUMI, Y NISHIDA, M NAMBA…
Journal of interferon & cytokine research, 1996liebertpub.com
The effects of interferon-γ (IFN-γ) on platelet recovery were examined in mice with marrow
aplasia induced by ip injection of 250 mg/kg of 5-fluorouracil (5-FU). The cytokine was
administrated by microosmotic pump, with an ability to deliver a consistent intact dose of
cytokine for 7 consecutive days. Administration of 250 IU/kg/day of IFN-γ in combination with
103 U/kg/day of IL-3, which alone had no effect on platelet counts, diminished the nadir for
platelet count and shortened the duration of thrombocytopenia. The effect was comparable …
The effects of interferon-γ (IFN-γ) on platelet recovery were examined in mice with marrow aplasia induced by i.p. injection of 250 mg/kg of 5-fluorouracil (5-FU). The cytokine was administrated by microosmotic pump, with an ability to deliver a consistent intact dose of cytokine for 7 consecutive days. Administration of 250 IU/kg/day of IFN-γ in combination with 103 U/kg/day of IL-3, which alone had no effect on platelet counts, diminished the nadir for platelet count and shortened the duration of thrombocytopenia. The effect was comparable to that of higher doses of IL-3 (10s U/kg/day). The administration of 250 IU/kg/day of IFN-γ in combination with 103 U/kg/day of IL-3 also induced megakaryocyte proliferation in bone marrow cell cultures. Single administration of either 250 IU/kg/day of IFN-γ or 103 U/kg/day of IL-3 had no significant effects. The effect of this combination was also comparable to that of a higher dose of IL-3 (105 U/kg/day). We suggest that IFN-γ accelerates megakaryocyte development, which leads to platelet production in chemotherapy-induced marrow aplasia. The administration of IFN-γ in combination with IL-3 might be useful for the management of marrow aplasia.
Mary Ann Liebert